Drug Research
Recipharm signs Memorandum of Understanding (MOU) for the fill finish of vaccines and biotherapeutics in Morocco
Global contract development and manufacturing organisation (CDMO), Recipharm, has signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan...
News
Tech Mahindra partners StaTwig for blockchain-based traceability solution for vaccine supply chain
IT major Tech Mahindra said it has partnered with StaTwig, a Singapore and Hyderabad-based digital supply chain solution provider, to implement vaccine traceability platform...
Drug Research
GSK and Alector to develop antibodies for neurodegenerative diseases
GlaxoSmithKline plc and Alector announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101)...
News
Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
Sosei Group Corporation, the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC, a global leader in pioneering the application of...
News
Fujifilm to invest additional $850m in FDB to expand capacity for biologics
Fujifilm has unveiled its plans to invest JPY90bn ($850m) in its subsidiary Fujifilm Diosynth Biotechnologies (FDB) to expand its capacity for biologics.
FDB is a...
News
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapores Bioprocessing Technology Institute
Waters Corporation announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology...
Clinical Trials
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read